Skyrizi (risankizumab-rzaa) is a biologic drug approved by the FDA for treating adults with moderate to severe plaque psoriasis. It works by inhibiting interleukin (IL)-23, a chemical messenger involved in autoimmune attacks, thus preventing the overproduction of IL-23 in the immune system.
Key Points about Skyrizi
- Show Full Answer
Skyrizi (risankizumab-rzaa) is a biologic drug approved by the FDA for treating adults with moderate to severe plaque psoriasis. It works by inhibiting interleukin (IL)-23, a chemical messenger involved in autoimmune attacks, thus preventing the overproduction of IL-23 in the immune system.
Key Points about Skyrizi:
- Administration: Subcutaneous injection every 12 weeks after initial loading doses.
- Common Side Effects: Upper respiratory infections, headache, fatigue, injection site reactions, and ringworm.
- Serious Side Effects: Increased risk for serious infections, including tuberculosis.
For more details, you can visit the Skyrizi website: [Skyrizi — AbbVie](https://www.skyrizi.com).
June 8, 2024
Join
Your Privacy Choices
